Abivax Sa ADR (ABVX)

$114.53 -6.47 (-5.35%)
Market Cap 9.59B
Revenue (ttm) 0.00
Net Income (ttm) -380.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 943,900
Avg Vol 960,794
Day's Range N/A - N/A
Shares Out 79.29M
Stochastic %K 1%
Beta 0.84
Analysts Strong Sell
Price Target $150.83

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 53 83 09 63
Address:
7-11 Boulevard Haussmann, Paris, France
CrispDry
CrispDry May. 16 at 12:55 AM
$ABVX next time it’s at 128-130 I’ll close it out. Hope we get a run up into June
0 · Reply
Hognose
Hognose May. 15 at 7:59 PM
$ABVX dip into the 110 or lower buy
0 · Reply
Hognose
Hognose May. 15 at 7:45 PM
$ABVX told ya. Glad I sold calls
0 · Reply
TornadoChasers
TornadoChasers May. 15 at 4:52 PM
$ECOX $GOAI $ABVX $MVIS LONG IT
1 · Reply
autographic
autographic May. 15 at 3:27 PM
$ABVX 🚨 $115 added ahead of maintenance . Pull back to low range. Next gen IBD potential.
1 · Reply
AsherLev
AsherLev May. 15 at 2:01 AM
$ABVX price doesn’t mean much to me at this point as in about 30/45 days they’re gonna come out or with great result and this thing gonna go to 175-200$ or bad ones and it will dive to…
0 · Reply
Hognose
Hognose May. 14 at 5:12 PM
$ABVX dip back down to 110 - 106. Then pop again.
0 · Reply
lordBrian
lordBrian May. 14 at 5:05 PM
$SLS is the next $ABVX :)
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 3:53 PM
$SLS We Will Be in Double Digits, at least $10 when the 80th Event is announced, and then the Share Price Launches. - 80th Event has Likely already Occurred - waiting for Data to Cycle through the PROCESS> $RVMD added $15B in Market Value the 48 hours after its P3 Results were announced. $ABVX was bumping around $5 , Stock doubled to $10 in the days ahead of its P3. T1 TRADING HALT on the ANNOUNCEMENT - and a + 600% GAP UP OPEN at $60 and it KEPT CLIMBING to a HIGH of $148 [+14.7B in Mcap] --- Based on P3 TRIAL DATA - SAME THING Similar will be Happening Here.
1 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 14 at 2:25 PM
$RVMD $SLS $ABVX SLS mirroring exactly what happened at RVMD and ABVX before the big phase 3 positive data releases. RVMD MC over $32 Billion now. ✌️🙏
0 · Reply
Latest News on ABVX
Abivax put volume heavy and directionally bearish

2026-05-12T18:20:45.000Z - 4 days ago

Abivax put volume heavy and directionally bearish

Abivax Repurchases Royalty Certificates And Prices $45M ADS Offering To Strengthen Balance Sheet

2026-05-05T09:39:36.000Z - 11 days ago

Abivax Repurchases Royalty Certificates And Prices $45M ADS Offering To Strengthen Balance Sheet

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

May 5, 2026, 2:00 AM EDT - 11 days ago

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

ABVX

Abivax call volume above normal and directionally bullish

2026-04-28T14:50:09.000Z - 18 days ago

Abivax call volume above normal and directionally bullish

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Apr 22, 2026, 4:05 PM EDT - 24 days ago

Abivax to Present Data on Obefazimod at Digestive Disease Week®

ABVX

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Apr 20, 2026, 4:05 PM EDT - 26 days ago

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

ABVX

Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF

2026-04-09T09:15:22.000Z - 5 weeks ago

Abivax price target raised to EUR 120 from EUR 88 at Oddo BHF

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Tue, 07 Apr 2026 15:00:00 -0400 - 5 weeks ago

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Abivax appoints Michael Nesrallah as chief commercial officer

2026-04-01T20:21:24.000Z - 6 weeks ago

Abivax appoints Michael Nesrallah as chief commercial officer

TAK

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Apr 1, 2026, 4:05 PM EDT - 6 weeks ago

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

ABVX

2 Healthcare Stocks That Could Soar Over the Next 5 Years

Thu, 26 Mar 2026 17:30:00 -0400 - 7 weeks ago

2 Healthcare Stocks That Could Soar Over the Next 5 Years

Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC

Mar 24, 2026, 11:42 AM EDT - 7 weeks ago

Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC

ABVX

Abivax price target raised to $148 from $142 at Barclays

2026-03-24T09:30:12.000Z - 7 weeks ago

Abivax price target raised to $148 from $142 at Barclays

– Abivax SA American Depositary Shares options imply 8.3% move in share price post-earnings

2026-03-23T17:06:03.000Z - 7 weeks ago

– Abivax SA American Depositary Shares options imply 8.3% move in share price post-earnings

2 Healthcare Stocks to Buy Before They Get Bought Out

Fri, 20 Mar 2026 05:34:00 -0400 - 2 months ago

2 Healthcare Stocks to Buy Before They Get Bought Out

Abivax initiated with a Buy at Jefferies

2026-03-16T00:15:14.000Z - 2 months ago

Abivax initiated with a Buy at Jefferies

Abivax spokesperson denies takeover rumors reported by French media

Mar 12, 2026, 10:33 AM EDT - 2 months ago

Abivax spokesperson denies takeover rumors reported by French media

ABVX

Abivax says ‘we deny the rumors’ to Bloomberg after takeover report

2026-03-12T14:10:32.000Z - 2 months ago

Abivax says ‘we deny the rumors’ to Bloomberg after takeover report

AZN

Abivax jumps 15% to $129.11 after report of exclusivity with AstraZeneca

2026-03-12T09:51:46.000Z - 2 months ago

Abivax jumps 15% to $129.11 after report of exclusivity with AstraZeneca

AZN

AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports

2026-03-12T09:51:37.000Z - 2 months ago

AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports

AZN

Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year

Tue, 10 Mar 2026 16:00:00 -0400 - 2 months ago

Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year

2 Reasons Abivax Stock Could 10X by 2036

Fri, 27 Feb 2026 14:45:00 -0500 - 2 months ago

2 Reasons Abivax Stock Could 10X by 2036

Abivax initiated with an Underperform at Wedbush

2026-02-24T11:52:54.000Z - 2 months ago

Abivax initiated with an Underperform at Wedbush

Wedbush initiates Abivax with an Underperform, urges caution

2026-02-24T11:51:55.000Z - 2 months ago

Wedbush initiates Abivax with an Underperform, urges caution

Abivax initiated with a Neutral at Wedbush

2026-02-24T11:45:15.000Z - 2 months ago

Abivax initiated with a Neutral at Wedbush

Abivax presents preclinical data for obefazimod

2026-02-22T18:55:09.000Z - 2 months ago

Abivax presents preclinical data for obefazimod

ABVX

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Feb 21, 2026, 6:00 AM EST - 3 months ago

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

ABVX

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Tue, 10 Feb 2026 20:11:00 -0500 - 3 months ago

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Better Long-Term Buy: This Emerging Player or the Industry Leader?

Fri, 30 Jan 2026 15:30:00 -0500 - 3 months ago

Better Long-Term Buy: This Emerging Player or the Industry Leader?

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

Jan 20, 2026, 6:01 AM EST - 4 months ago

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

ABVX LLY

Prediction: This Healthcare Stock Could Soar by 72% in 2026

Mon, 19 Jan 2026 15:45:00 -0500 - 4 months ago

Prediction: This Healthcare Stock Could Soar by 72% in 2026

France has had no request for investment approval in biotech Abivax - official

Jan 12, 2026, 9:49 AM EST - 4 months ago

France has had no request for investment approval in biotech Abivax - official

ABVX LLY

Abivax stock rockets 30% on Eli Lilly takeover speculation

Jan 12, 2026, 9:32 AM EST - 4 months ago

Abivax stock rockets 30% on Eli Lilly takeover speculation

ABVX LLY

Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid

Jan 12, 2026, 5:03 AM EST - 4 months ago

Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid

ABVX LLY

Abivax shares soar 23% as media report reignites M&A chatter

Jan 12, 2026, 4:38 AM EST - 4 months ago

Abivax shares soar 23% as media report reignites M&A chatter

ABVX LLY

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Jan 9, 2026, 6:54 AM EST - 4 months ago

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

ABVX LLY

Abivax Provides 2026 Corporate Outlook

Jan 7, 2026, 4:05 PM EST - 4 months ago

Abivax Provides 2026 Corporate Outlook

ABVX

Why Abivax Stock Was on Fire Today

Mon, 22 Dec 2025 19:09:18 -0500 - 5 months ago

Why Abivax Stock Was on Fire Today

Abivax to be Added to Nasdaq Biotechnology Index

Dec 18, 2025, 4:05 PM EST - 5 months ago

Abivax to be Added to Nasdaq Biotechnology Index

ABVX

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Dec 17, 2025, 4:05 PM EST - 5 months ago

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

ABVX

French biotech Abivax's shares climb on Eli Lilly bid rumors

Dec 10, 2025, 5:52 AM EST - 5 months ago

French biotech Abivax's shares climb on Eli Lilly bid rumors

ABVX LLY

2 Under-the-Radar Stocks That Have Soared This Year

Tue, 09 Dec 2025 16:45:00 -0500 - 5 months ago

2 Under-the-Radar Stocks That Have Soared This Year

ABIVAX Société Anonyme Transcript: The United European Gastroenterology (UEG) Congress UEG Week 2025

Oct 6, 2025, 9:00 AM EDT - 7 months ago

ABIVAX Société Anonyme Transcript: The United European Gastroenterology (UEG) Congress UEG Week 2025

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Oct 5, 2025, 11:00 AM EDT - 7 months ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

ABVX

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Sep 29, 2025, 4:05 PM EDT - 8 months ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

ABVX

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Sep 23, 2025, 4:05 PM EDT - 8 months ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

ABVX

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Sep 12, 2025, 11:45 AM EDT - 8 months ago

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

ABVX

Abivax Presents First Half 2025 Financial Results

Sep 8, 2025, 4:00 PM EDT - 8 months ago

Abivax Presents First Half 2025 Financial Results

ABVX

How Hedge Funds Won Big on an Obscure Drugmaker

Aug 30, 2025, 5:30 AM EDT - 9 months ago

How Hedge Funds Won Big on an Obscure Drugmaker

ABVX

This Stock Is Up by 800% This Year -- but Is It a Buy?

Thu, 31 Jul 2025 10:00:00 -0400 - 10 months ago

This Stock Is Up by 800% This Year -- but Is It a Buy?

Abivax Announces Closing of $747.5 Million Public Offering

Jul 28, 2025, 4:15 PM EDT - 10 months ago

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Jul 25, 2025, 2:00 AM EDT - 10 months ago

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Jul 24, 2025, 8:40 AM EDT - 10 months ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Jul 24, 2025, 8:40 AM EDT - 10 months ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Jul 24, 2025, 1:30 AM EDT - 10 months ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Jul 23, 2025, 4:15 PM EDT - 10 months ago

Abivax Announces Launch of Public Offering

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Jun 11, 2025, 4:00 PM EDT - 1 year ago

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Presents First Quarter 2025 Financial Results

Jun 2, 2025, 4:00 PM EDT - 1 year ago

Abivax Presents First Quarter 2025 Financial Results

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

Jun 2, 2025, 11:00 AM EDT - 1 year ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

JNJ LLY

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Apr 29, 2025, 4:05 PM EDT - 1 year ago

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Apr 22, 2025, 4:00 PM EDT - 1 year ago

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Mar 26, 2025, 5:05 PM EDT - 1 year ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Mar 24, 2025, 3:30 AM EDT - 1 year ago

Abivax Announces Full Year 2024 Financial Results

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Feb 21, 2025, 2:30 AM EST - 1 year ago

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Jan 28, 2025, 2:30 AM EST - 1 year ago

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Jan 23, 2025, 4:05 PM EST - 1 year ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Jan 9, 2025, 11:35 AM EST - 1 year ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Dec 23, 2024, 4:05 PM EST - 1 year ago

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 19, 2024, 4:30 PM EST - 1 year ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Nov 14, 2024, 4:01 PM EST - 1 year ago

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Nov 13, 2024, 4:01 PM EST - 1 year ago

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Oct 3, 2024, 4:01 PM EDT - 1 year ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Oct 3, 2024, 2:31 AM EDT - 1 year ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Sep 26, 2024, 2:30 AM EDT - 1 year ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Sep 25, 2024, 4:01 PM EDT - 1 year ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

CrispDry
CrispDry May. 16 at 12:55 AM
$ABVX next time it’s at 128-130 I’ll close it out. Hope we get a run up into June
0 · Reply
Hognose
Hognose May. 15 at 7:59 PM
$ABVX dip into the 110 or lower buy
0 · Reply
Hognose
Hognose May. 15 at 7:45 PM
$ABVX told ya. Glad I sold calls
0 · Reply
TornadoChasers
TornadoChasers May. 15 at 4:52 PM
$ECOX $GOAI $ABVX $MVIS LONG IT
1 · Reply
autographic
autographic May. 15 at 3:27 PM
$ABVX 🚨 $115 added ahead of maintenance . Pull back to low range. Next gen IBD potential.
1 · Reply
AsherLev
AsherLev May. 15 at 2:01 AM
$ABVX price doesn’t mean much to me at this point as in about 30/45 days they’re gonna come out or with great result and this thing gonna go to 175-200$ or bad ones and it will dive to…
0 · Reply
Hognose
Hognose May. 14 at 5:12 PM
$ABVX dip back down to 110 - 106. Then pop again.
0 · Reply
lordBrian
lordBrian May. 14 at 5:05 PM
$SLS is the next $ABVX :)
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 14 at 3:53 PM
$SLS We Will Be in Double Digits, at least $10 when the 80th Event is announced, and then the Share Price Launches. - 80th Event has Likely already Occurred - waiting for Data to Cycle through the PROCESS> $RVMD added $15B in Market Value the 48 hours after its P3 Results were announced. $ABVX was bumping around $5 , Stock doubled to $10 in the days ahead of its P3. T1 TRADING HALT on the ANNOUNCEMENT - and a + 600% GAP UP OPEN at $60 and it KEPT CLIMBING to a HIGH of $148 [+14.7B in Mcap] --- Based on P3 TRIAL DATA - SAME THING Similar will be Happening Here.
1 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 14 at 2:25 PM
$RVMD $SLS $ABVX SLS mirroring exactly what happened at RVMD and ABVX before the big phase 3 positive data releases. RVMD MC over $32 Billion now. ✌️🙏
0 · Reply
TheGunnerAB
TheGunnerAB May. 13 at 9:15 PM
$ABVX someone did an interesting asymmetrical July butterfly today: Bought 1,000 of the $95 Calls Sold 2,000 of the $150 Calls Bought 1,000 of the $195 Calls. Total premium paid $1.725M. Downside breakeven at $112.5. At $150, return of $5.5M on $1.725M investment.
1 · Reply
Stonski
Stonski May. 13 at 2:27 PM
$ABVX $SLS for all the penny flippers here have ur fun im holding for the ES MONEY 😂
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 13 at 2:22 PM
$SLS $6.16 is about to be $16.60 enroute to $60 and Climbing. The positive P3 Result is worth $40B to Big Pharma. Buy and Hold $ABVX was a $5 stock - it doubled to $10 in the days ahead of releasing its P3 Results --- T1 Trading Halt on the P3 Announcement and a Gap UP 600% to $60 Per Share and it Kept Climbing to a High of $148. Something Very Similar will be Happening Here/ ANY DAY NOW.
0 · Reply
Hognose
Hognose May. 13 at 9:48 AM
$ABVX current price targets range around 150. June read out, likely to explode to 180.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 13 at 7:20 AM
$SLS $ABVX $10 to $15 THIS Week. Phase 3 Results worth 50x the Current Share Price Are COMING - it is INEVITABLE --- The 80th EVENT PR Will Be Announced, and the Share Price Will Launch Given all that VALUE on the Table. — ask your AI what a $28B TAM is worth to Big Pharma. - The 150 Institutional Funds invested here will be loading in.
0 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 13 at 5:19 AM
$ABVX $SLS Greg ABVX doesn’t have a WT1 CURATIVE cancer platform for 20+ Cancer types like Sellas. GPS Regal Pivotal Registrational phase 3 Revolutionary results will unleash The KRAKEN and devour any short in sight to $280.00+ 😉 ✌️❤️‍🩹👏
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 13 at 5:05 AM
$SLS 78th Event PR - Phase 3 Results for a Revolutionary AML Remission Immunotherapy are Now Officially Imminent. BE HOLDING and HOLD ON TIGHT. $ABVX was a $5 Stock in the Days Leading up to its P3 Result it Doubled to $10 --- When the P3 Result was Announced - there was T1 TRADING HALT - and GAP UP 600% - to $60 In and Instant -- and it Kept CLIMBING to a HIGH OF $148 ... Something Very Similar is about to Happen Here - any day now.
1 · Reply
DipinDipout
DipinDipout May. 13 at 12:18 AM
$ABVX BLOCK all SLS PUMPERS that are eating a dumpster
0 · Reply
DipinDipout
DipinDipout May. 13 at 12:16 AM
$ABVX @Jesse1011 @55X_ROI_Q1_2026 SLS IS GARBAGE - nice try pumper
0 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 12 at 11:19 PM
$SLS $RVMD $ABVX Long Brothers and Sisters as I said earlier today Don’t step on hundred Dollar 💵 Bills to pick up Pennie’s. Have the Conviction to hold till $280.00+ it’s coming. ABVX + RVMD will look like child’s play when this moves it will be one ☝️ of the most violent uptick in the History of the Wall Street. ✌️🙏❤️‍🩹
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 10:30 PM
$ABVX Price: $121.39 (-0.61%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.89% RSI: 56.9 | Momentum: Moderate Volume: -14.9% vs avg Volatility: 3.56% Support: $106.00 | Resistance: $129.18 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 12 at 9:34 PM
$SLS From $5 to $148 --- in a matter of days - based on P3 data. BE HOLDING and HOLD ON TIGHT. $ABVX was a $5 Stock in the Days Leading up to its P3 Result it Doubled to $10 --- When the Result was Announced - there was T1 TRADING HALT - and GAP UP 600% to $60 In and Instant -- and it Kept CLIMBING to a HIGH OF $148 ... Something Very Similar is about to Happen Here - any day now.
1 · Reply